Dean of Research at SMD / Professor of Immunopharmacology
Mauro has published over 300 papers, with >17,000 citations and an H Factor of 72 (Google Scholar).
After BSc in Pharmaceutical Chemistry (University in Florence, 1985) and a MSc in Pharmacology and Toxicology (1988), Mauro started his career at the Sclavo Research Centre under the leadership of Prof Luca Parente. In 1991 he joined Prof Rod Flower at the William Harvey Research Institute, and in 1996 he gained his PhD (LON).
Mauro career has been shaped by fellowships from the Arthritis Research Campaign, a post-doctoral one (1997-2002) followed by a senior fellowship (2002-2007). In 2001 Mauro gained his personal chair by Queen Mary University of London. Centre Lead from 2001-to 2013, Mauro acted as Deputy Director of the William Harvey Research Institute from 2006 to 2013, taking on Co-Directorship in 2013. In 2015 he became Dean for Research and Research Impact of the Faculty of Medicine and Dentistry.
Mauro is Fellow of the British Pharmacological Society (FBPhS, 2004), of the Academia Europea (2010) and foreign member of the Brazilian Academy of Sciences (2015).
Summary of Research
We pioneered the concept that acute inflammation resolves, naturally, by the engagement of endogenous mediators that activate a series of non-redundant processes (inhibition of immune cell trafficking, efferocytosis, tissue repair) typical of what we now call the Resolution of Inflammation. When resolution is malfunctioning it contributes to chronic inflammatory diseases. We study the pathophysiology of some pro-resolving pathways (eg. Annexin A1 and its peptides, Glucocorticoids+calcitonin, Melanocortins, omega-3 derivatives) and aim to identify novel receptors amenable for the development of innovative anti-inflammatory therapeutics. A current focus is on pro-resolving GPCRs, such as FPR2/ALX and MC3, establishing their expression in disease; homo/heterodimerization and discovering novel biological functions.
Molecular pharmacology and cell biology protocols are complemented by integrated biology models (intravital microscopy for vascular responses, peritonitis, paw oedema, airpouch) including models of disease (arthritis, myocardial infarct and stroke). Each project is different in its practicality since it is the scientific question that drives the experimental protocols to be applied or developed, hence creativity is a must!
We are acutely aware of the importance to assess the relevance of our research in clinical settings, as this would accelerate the development of innovative therapeutics modelled on resolution; currently, the focus is on rheumatology, cardiac surgery, sepsis and vasculitides.
Expression of the pro-resolving receptor FPR2 (a GPCR that transduces the actions of AnnexinA1 and Lipxin A4) as revealed by Green Florescence Protein detection, using a unique mouse colony engineered with this reporter under FPR2 promoter (funded by The Wellcome Trust).
Microcapsules (MC; green) can be used to deliver biologically active molecules to modulate the interaction between human leukocytes and the endothelium. (Collaboration with Prof Sukhorukov, QMUL).
Members of the Group
For a full list of publist publications click here
Headland SE, Jones HR, Norling LV, Kim A, Souza PR,Corsiero E, Gil CD, Nerviani A, Dell'Accio F, Pitzalis C, Oliani SM, Jan LY, Perretti M. Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis. Sci Transl Med. 2015 Nov 25;7(315):315ra190. doi: 10.1126/scitranslmed.aac5608. PubMed PMID: 26606969.
Federici Canova D, Pavlov AM, Norling LV, Gobbetti T, Brunelleschi S, Le Fauder P, Cenac N, Sukhorukov GB, Perretti M. Alpha-2-macroglobulin loaded microcapsules enhance human leukocyte functions and innate immune response. J Control Release. 2015 Nov 10;217:284-92. doi: 10.1016/j.jconrel.2015.09.021. Epub 2015 Sep 16. PubMed PMID: 26385167; PubMed Central PMCID: PMC4649706.
McArthur S, Gobbetti T, Kusters DH, Reutelingsperger CP, Flower RJ, Perretti M. Definition of a Novel Pathway Centered on Lysophosphatidic Acid To Recruit Monocytes during the Resolution Phase of Tissue Inflammation. J Immunol. 2015 Aug 1;195(3):1139-51. doi: 10.4049/jimmunol.1500733. Epub 2015 Jun 22. PubMed PMID: 26101324; PubMed Central PMCID: PMC4505961.
Montero-Melendez T, Gobbetti T, Cooray SN, Jonassen TE, Perretti M. Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects. J Immunol. 2015 Apr 1;194(7):3381-8. doi: 10.4049/jimmunol.1402645. Epub 2015 Feb 27. PubMed PMID: 25725103.
Gobbetti T, Coldewey SM, Chen J, McArthur S, leFaouder P, Cenac N, Flower RJ, Thiemermann C, Perretti M. Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18685-90. doi: 10.1073/pnas.1410938111. Epub 2014 Dec 15. PubMed PMID: 25512512; PubMed Central PMCID: PMC4284560.
Thompson D, McArthur S, Hislop JN, Flower RJ, Perretti M. Identification of a novel recycling sequence in the C-tail of FPR2/ALX receptor: association with cell protection from apoptosis. J Biol Chem. 2014 Dec 26;289(52):36166-78. doi: 10.1074/jbc.M114.612630. Epub 2014 Oct 17. PubMed PMID: 25326384; PubMed Central PMCID: PMC4276880.
Montero-Melendez T, Madeira MF, Norling LV, Alsam A, Curtis MA, da Silva TA, Perretti M. Association between periodontal disease and inflammatory arthritis reveals modulatory functions by melanocortin receptor type 3. Am J Pathol. 2014 Aug;184(8):2333-41. doi: 10.1016/j.ajpath.2014.04.009. Epub 2014 Jun 27. PubMed PMID: 24979595; PubMed Central PMCID: PMC4116693.
Locatelli I, Sutti S, Jindal A, Vacchiano M, Bozzola C, Reutelingsperger C, Kusters D, Bena S, Parola M, Paternostro C, Bugianesi E, McArthur S, Albano E, Perretti M. Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. Hepatology. 2014 Aug;60(2):531-44. doi: 10.1002/hep.27141. Epub 2014 May 12. PubMed PMID: 24668763; PubMed Central PMCID: PMC4258084.
Dalli J, Norling LV, Montero-Melendez T, Federici Canova D, Lashin H, Pavlov AM, Sukhorukov GB, Hinds CJ, Perretti M. Microparticle alpha-2-macroglobulin enhances pro-resolving responses and promotes survival in sepsis. EMBO Mol Med. 2014 Jan;6(1):27-42. doi: 10.1002/emmm.201303503. Epub 2013 Dec 15. PubMed PMID: 24357647; PubMed Central PMCID: PMC3936490.
Nadkarni S, Dalli J, Hollywood J, Mason JC, Dasgupta B, Perretti M. Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression. Circ Res. 2014 Jan 17;114(2):242-8. doi: 10.1161/CIRCRESAHA.114.301374. Epub 2013 Oct 24. PubMed PMID: 24158630.
How Microvesicles could revolutionise arthritis treatment
Neutrophil microvesicles protect cartilage in arthritis
New Class of Anti-Arthritis Drugs Effectively Treats Multiple Inflammatory Diseases
American Journal of Pathology
Internal: Dr Michele Bombardieri; Dr FulvioD’Acquisto; Prof Federica Marelli-Berg; Dr Charles Hinds; Prof Sussan Nourshargh; Prof Cos Pitzalis; Dr Egle Solito; Prof Gleb Sukhorukov; Prof Chris Thiemermann.
External: B Dasgupta (Southend University Hospital); S Farsky (USP, Sao Paulo, Brazil); J Mason (Imperial College); A Nusrat (Emory University, Atlanta); SM Oliani (UNESP, Sao José do Rio Preto, Brazil); C Reutelingsperger (Maastricht University); CN Serhan (Harvard Medical School, Boston); MM Teixeira (UNMG, Belo Horizonte, Brazil); N Vergnolle (INSERM, Toulouse); JL Wallace (McMaster University, Hamilton); V Witko-Sarsat (Cochin Hopital, Paris).
Industrial: N Mehta; A Consalvo (Unigene Corporation); T Jonassen (SynAct Pharma ApS, Aarhus); A Moore (UCB Celltech, Slough); D Taylor; A Kamal (MRC Technology, London).
Mauro Perretti, PhD, FBPharmacolS, FSB
Professor of Immunopharmacology
Dean of Research and Research Impact SMD
Co-Director William Harvey Research Institute
Barts and The London School of Medicine
Queen Mary University of London
London, EC1M 6BQ
T: +44 (0) 20 7882 8782
Miss Silvia Ayguade
T: +44 (0) 20 7882 8783